Time to Take the Lead – Practical Utilization of SGLT2 Inhibitors

Published: 18 December 2020

  • Views:

    Views Icon 55

  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

This independent medical education symposium was supported by a grant from the Boehringer Ingelheim & Eli Lilly and Company alliance.

Learning objectives

  • Understand current guidelines and utilisation of SGLT2i
  • Describe the potential mechanism of benefit of SGLT2i
  • Initiate and manage SGLT2i in appropriate patients

More from this programme

Part 1

Introduction, and No Permission Needed – Cardiology Guidelines + Prescribing Practice

1 session
Introduction, and No Permission Needed – Cardiology Guidelines + Prescribing Practice Watch now

Part 2

SGLT2i are Cardiovascular Drugs

1 session
SGLT2i are Cardiovascular Drugs Watch now

Part 3

Cardiologists Taking the Lead – How Can We Use SGLT2 Inhibitors in Our Clinical Practice?

1 session
Cardiologists Taking the Lead – How Can We Use SGLT2 Inhibitors in Our Clinical Practice? Watch now

Part 4

Case Discussion

1 session
Case Discussion Watch now

Part 5

A Follow-up Discussion to the ESC 2020 Session

1 session
A Follow-up Discussion to the ESC 2020 Session Watch now

Faculty Biographies

Stefan Anker

Stefan Anker

Professor of Cardiology

Dr Stefan D Anker, Professor of Cardiology and Cachexia Research, Department of Cardiology, Charité Campus Virchow-Klinikum, Berlin, Germany, and served as the 2012–14 President of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). 

View full profile